Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer

Although BRCA1-deficient tumors are extremely sensitive to DNA-damaging drugs and poly(ADP-ribose) polymerase (PARP) inhibitors, recurrences do occur and, consequently, resistance to therapy remains a serious clinical problem. To study the underlying mechanisms, we induced therapy resistance in pati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI : Journal of the National Cancer Institute Jg. 108; H. 11
Hauptverfasser:	Ter Brugge, Petra, Kristel, Petra, van der Burg, Eline, Boon, Ute, de Maaker, Michiel, Lips, Esther, Mulder, Lennart, de Ruiter, Julian, Moutinho, Catia, Gevensleben, Heidrun, Marangoni, Elisabetta, Majewski, Ian, Józwiak, Katarzyna, Kloosterman, Wigard, van Roosmalen, Markus, Duran, Karen, Hogervorst, Frans, Turner, Nick, Esteller, Manel, Cuppen, Edwin, Wesseling, Jelle, Jonkers, Jos
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 01.11.2016
Schlagworte:	Animals Antineoplastic Agents - therapeutic use BRCA1 Protein - deficiency Cisplatin - therapeutic use DNA Methylation Drug Resistance, Neoplasm - genetics Female Gene Expression Gene Fusion Genes, BRCA1 Humans Melphalan - therapeutic use Mice Mutation Neoplasm Transplantation Nimustine - therapeutic use Phthalazines - therapeutic use Piperazines - therapeutic use Promoter Regions, Genetic Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - genetics
ISSN:	1460-2105
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!